Tenaya Therapeutics Unveils Participation in Key Investor Events
Tenaya Therapeutics' Upcoming Investor Participation
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company, is set to share insights on its innovative therapies targeting heart disease in various investor and industry conferences this October. Faraz Ali, the CEO of Tenaya Therapeutics, will lead discussions at significant conferences, highlighting the company’s commitment to developing potentially curative treatments.
Overview of Conference Details
During the month of October, Tenaya Therapeutics will participate in key discussions at notable events, emphasizing the advancements in gene therapy and treatment strategies for heart disease. Here are the details of the upcoming conferences:
Cell & Gene Meeting on the Mesa
On October 6, Tenaya Therapeutics will engage in a panel discussion titled "Future Horizons: Emerging Trends and Opportunities in Cell and Gene Therapy Development" from 8:00 AM MT to 9:00 AM MT. Additionally, a company presentation will follow at 12:00 PM MT, presenting further insights into their innovative therapies.
Chardan Annual Genetic Medicines Conference
The important conversation will continue at the Chardan Annual Genetic Medicines Conference on October 21, where Tenaya will present insights during a panel discussion from 12:00 PM ET to 12:40 PM ET. The focus here will be on "In Vivo Gene Therapies for Genetic Cardiac Diseases," shedding light on their groundbreaking work in this area.
Webcast Information
Investors interested in the discussions can access the live webcast during the conferences through Tenaya's website, ensuring that stakeholders stay informed about these pivotal topics. After the events, archived replays of the presentations will be available on the company's website for approximately 30 days, making it easier for interested parties to catch up on discussions they might have missed.
About Tenaya Therapeutics
Tenaya Therapeutics stands out as a pioneering force in the biotechnology landscape, dedicated to addressing the root causes of heart disease. With a focus on genetic therapies, their pipeline includes clinical-stage candidates aimed at treating conditions such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC). Their efforts are bolstered by integrated internal capabilities, including target validation and advanced manufacturing processes.
Future Aspirations
Looking ahead, Tenaya Therapeutics is committed to expanding its portfolio of innovative treatments. Alongside TN-201 and TN-401, Tenaya is also working on other promising candidates, including TN-301, which aims to target heart failure. This holistic pipeline showcases the company's strategic focus on both rare and more prevalent heart issues, with an aim to change the treatment landscape for patients significantly.
Contact Information for Inquiries
For more information, Tenaya Therapeutics can be reached through their corporate communications team, led by Michelle Corral, VP of Corporate Communications and Investor Relations. Interested parties can contact her at IR@tenayathera.com. Additionally, for inquiries related to investor relations, Anne-Marie Fields at Precision AQ is available at annemarie.fields@precisionaq.com.
Frequently Asked Questions
What is Tenaya Therapeutics' main focus?
Tenaya Therapeutics is focused on developing therapies that target the underlying causes of heart disease.
When will the conferences take place?
The upcoming conferences will take place on October 6 and October 21.
Where can I access the conference webcasts?
Webcasts will be available through Tenaya's website during the events and archived for 30 days afterward.
What therapies are in Tenaya's pipeline?
Therapies in Tenaya's pipeline include TN-201 for HCM and TN-401 for ARVC, among others.
Who can I contact for more information?
Michelle Corral is the contact for corporate communications, and inquiries can also be directed to Anne-Marie Fields for investor relations.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.